L-Glutamine

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

Brand name
L-Glutamine
Generic name
L-GLUTAMINE
Manufacturer
ANI Pharmaceuticals, Inc.
Product type
HUMAN PRESCRIPTION DRUG
SPL set ID
bb4ec712-14b7-47e3-8cb9-c71922712e55
SPL ID
0635706e-180e-435e-92cf-c85e0ca4f7e0
Version
2
Effective date
2025-08-07
Source export date
2026-09-28
Source partition
11
Source file
https://download.open.fda.gov/drug/label/drug-label-0011-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-09-28/aa96b5a2be6b394393acd0090f6948bdf99e0e8e00666f81608929c8fa83db77/drug-label-0011-of-0014.json.zip
Source manifest SHA-256
cd2e66336a5cd2223fa3995098fdbdb84c6a7ee5c0a4addb236ccb22dd1e6887
Import run
20260929T050834Z
Imported at
2026-09-29 06:16:50
Harmonized routes table
Harmonized routes
ORAL

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 1 of 1 · 2 matching rows.

adverse reactions

6 ADVERSE REACTIONS Most common adverse reactions (incidence > 10%) are constipation, nausea, headache, abdominal pain, cough, pain in extremity, back pain, and chest pain. (6) To report SUSPECTED ADVERSE REACTIONS, contact Novitium Pharma LLC at 1-855-204-1431 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The data described below reflect exposure to L-glutamine in 187 patients, including 136 exposed for 6 months and 109 exposed for ≥1 year. L-glutamine was studied in 2 placebo-controlled clinical trials (a phase 3 study, n=230 and a phase 2 study, n=70). In these trials, patients with sickle cell anemia or sickle β 0 -thalassemia were randomized to receive L-glutamine (n=187) or placebo (n=111) orally twice daily for 48 weeks followed by 3 weeks of tapering. Both studies included pediatric and adult patients (5-58 years of age) and 54% were female. The majority of patients were black (97.3%), had a diagnosis of sickle cell anemia (89.9%) and were receiving hydroxyurea at baseline (63.4%). Treatment discontinuation due to adverse reactions was reported in 2.7% (n=5) of patients receiving L-glutamine. These adverse reactions included one case each of hypersplenism, abdominal pain, dyspepsia, burning sensation, and hot flash. Serious adverse reactions were reported in both treatment groups, more frequently in the placebo group, and were consistent with the underlying disease. Three deaths (3/187=1.6%) occurred during the study in the L-glutamine treatment group as compared to none in the placebo treatment group. None of the deaths were considered to be related to L-glutamine treatment. Adverse reactions occurring in greater than 10% of patients treated with L-glutamine are shown in Table 2 below. Table 2. Adverse Reactions Occurring at an Incidence > 10% in Clinical Studies of L-glutamine Adverse reaction L-glutamine N = 187 (%) Placebo N = 111 (%) Constipation 21 18 Nausea 19 14 Headache 18 15 Abdominal Pain* 17 16 Cough 16 14 Pain in extremity 13 7 Back pain 12 5 Chest pain 12 8 *Abdominal pain = abdominal pain and abdominal pain, upper

adverse reactions table

<table cellspacing="0" cellpadding="0" border="0" width="563.4545"><colgroup><col width="57.3586687123805%"/><col width="20.8426767378732%"/><col width="21.7986545497463%"/></colgroup><tbody><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="middle"><content styleCode="bold">Adverse reaction</content> </td><td styleCode="Rrule" align="center" valign="middle"><content styleCode="bold">L-glutamine</content> <content styleCode="bold">N = 187</content> <content styleCode="bold">(%)</content> </td><td styleCode="Rrule" align="center" valign="middle"><content styleCode="bold">Placebo</content> <content styleCode="bold">N = 111</content> <content styleCode="bold">(%)</content> </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="middle">Constipation </td><td styleCode="Rrule" align="center" valign="middle">21 </td><td styleCode="Rrule" align="center" valign="middle">18 </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="middle">Nausea </td><td styleCode="Rrule" align="center" valign="middle">19 </td><td styleCode="Rrule" align="center" valign="middle">14 </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="middle">Headache </td><td styleCode="Rrule" align="center" valign="middle">18 </td><td styleCode="Rrule" align="center" valign="middle">15 </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="middle">Abdominal Pain* </td><td styleCode="Rrule" align="center" valign="middle">17 </td><td styleCode="Rrule" align="center" valign="middle">16 </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="middle">Cough </td><td styleCode="Rrule" align="center" valign="middle">16 </td><td styleCode="Rrule" align="center" valign="middle">14 </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="middle">Pain in extremity </td><td styleCode="Rrule" align="center" valign="middle">13 </td><td styleCode="Rrule" align="center" valign="middle">7 </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="middle">Back pain </td><td styleCode="Rrule" align="center" valign="middle">12 </td><td styleCode="Rrule" align="center" valign="middle">5 </td></tr><tr><td styleCode="Lrule Rrule" valign="middle">Chest pain </td><td styleCode="Rrule" align="center" valign="middle">12 </td><td styleCode="Rrule" align="center" valign="middle">8 </td></tr></tbody></table>

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.